Should We Perform Repeated Re-biopsy for the Detection of T790M Mutation?
Cancer Research and Treatment · 15.10.2023 · 55 (4) · 1190-1197
DOI: 10.4143/crt.2023.320 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Cancer Research and Treatment, erschienen am 15.10.2023. Verfasst von Saerom Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Pusan National University Hospital, National Research Foundation of Korea, Ministry of Science and ICT.
Abstract (Originalsprache)
Purpose
Epidermal growth factor receptor (EGFR) T790M mutations have been detected in the second or third rebiopsy, even if the T790M mutation was not identified in the first rebiopsy. This meta-analysis investigated the EGFR T790M mutation detection rates and its additional advantages with repeated rebiopsies.Materials and Methods We searched through the PubMed and EMBASE databases up to June 2022. Studies reporting rebiopsy to identify the EGFR T790M mutation in case of disease progression among patients with advanced non-small cell lung cancer and multiple rebiopsies were included. The quality of the included studies was checked using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool.
Results
Eight studies meeting the eligibility criteria, reporting 1,031 EGFR mutation–positive patients were selected. The pooled EGFR T790M mutation detection rate of the first and repeated rebiopsies were 0.442 (95% confidence interval [CI], 0.411 to 0.473; I2=84%; p < 0.01) and 0.465 (95% CI, 0.400 to 0.530; I2=69%; p < 0.01), respectively. Overall, the pooled detection rate of EGFR T790M mutation was 0.545 (95% CI, 0.513 to 0.576), which increased by 10.3% with repeated rebiopsies.
Conclusion
This meta-analysis identified that repeated rebiopsy increases the detection rate of EGFR T790M mutation by 10.3%, even if EGFR T790M mutation is not detected in the first rebiopsy. Our results indicate that the spatiotemporal T790M heterogeneity can be overcome with repeated rebiopsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
- Department of Biostatistics, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
- Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
Förderung
- Pusan National University Hospital
- National Research Foundation of Korea
- Ministry of Science and ICT
Zitieren
APA
Kim, S., Kim, S. H., Kim, J., Kim, M. H., Lee, M. K., & Eom, J. S. (2023). Should We Perform Repeated Re-biopsy for the Detection of T790M Mutation?. Cancer Research and Treatment, 55(4), 1190-1197. https://doi.org/10.4143/crt.2023.320
Vancouver
Kim S, Kim SH, Kim J, Kim MH, Lee MK, Eom JS. Should We Perform Repeated Re-biopsy for the Detection of T790M Mutation?. Cancer Research and Treatment. 2023;55(4):1190-1197. doi:10.4143/crt.2023.320
BibTeX
@article{Kim2023,
author = {Kim, Saerom and Kim, Soo Han and Kim, Jinmi and Kim, Mi-Hyun and Lee, Min Ki and Eom, Jung Seop},
title = {Should We Perform Repeated Re-biopsy for the Detection of T790M Mutation?},
journal = {Cancer Research and Treatment},
year = {2023},
volume = {55},
number = {4},
pages = {1190--1197},
doi = {10.4143/crt.2023.320}
}
EUVIMED